Central Pacific Bank - Trust Division’s Neurocrine Biosciences NBIX Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Hold	1,675	–	–	0.03%	412
2026 Q1	$221K	Sell	1,675 -50	-3%	-$6.63K	0.03%	436
2025 Q4	$245K	Hold	1,725	–	–	0.03%	404
2025 Q3	$242K	Hold	1,725	–	–	0.03%	410
2025 Q2	$217K	Buy	1,725 +100	+6%	+$11.5K	0.03%	426
2025 Q1	$180K	Sell	1,625 -2,077	-56%	-$263K	0.02%	463
2024 Q4	$505K	Sell	3,702 -1,200	-24%	-$148K	0.07%	262
2024 Q3	$565K	Sell	4,902 -2,335	-32%	-$320K	0.07%	261
2024 Q2	$996K	Buy	7,237 +937	+15%	+$128K	0.12%	181
2024 Q1	$891K	Buy	+6,300	New	+$860K	0.11%	208

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Central Pacific Bank - Trust Division's NBIX Position: Q2 2026 in Review

Central Pacific Bank - Trust Division held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 1,675 shares worth $282K. The position accounts for 0.03% of the portfolio, ranked #412.

Central Pacific Bank - Trust Division first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $996K in Q2 2024. 165 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Central Pacific Bank - Trust Division held 1,675 shares of Neurocrine Biosciences worth $282K as of Q2 2026.
Central Pacific Bank - Trust Division left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.03% of Central Pacific Bank - Trust Division's portfolio in Q2 2026, its #412 holding.
Central Pacific Bank - Trust Division first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
Central Pacific Bank - Trust Division's Neurocrine Biosciences position peaked at $996K in Q2 2024.
165 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Central Pacific Bank - Trust Division's 13F filing for Q2 2026, filed 7 Jul 2026.